What is Riluzole?

Riluzole is the first medicine the FDA approved for the treatment of ALS. Since 1995, it is still the only medicine shown to extend life in people with ALS. The American Academy of Neurology recommends that riluzole should be offered to all patients to slow the progression of ALS. Patients should ask their physician to start them on riluzole as soon as they receive a diagnosis.

Bottle of Tiglutik (riluzole)

For many years, riluzole was available only as a tablet. Tablets can be challenging for people with ALS because many people develop difficulty swallowing tablets or have a feeding tube (PEG tube). Because of these challenges, people are often told to crush their riluzole tablets. However, no studies have been done to show that this is safe to do. In some people, crushing riluzole tablets may make swallowing problems worse. Additionally, crushed tablets are the most common cause of PEG tubes getting clogged and occurs in 1 out of 3 patients.

TIGLUTIK is the only formulation of riluzole approved by the FDA for both oral and PEG tube use. It was developed specifically to meet the needs of people with ALS.  With TIGLUTIK, patients no longer have to crush their riluzole tablets.

Click here for information to Ask Your Doctor if TIGLUTIK is Right for you.



TIGLUTIK (riluzole) is a prescription medicine for the treatment of amyotrophic lateral sclerosis (ALS).

Important Safety Information

  • You should not take TIGLUTIK if you are allergic to any of its ingredients.
  • TIGLUTIK can cause liver injury, including death. Your doctor should do blood tests to check your liver function before and during your treatment and may stop treatment with TIGLUTIK if liver function is not normal. Contact your doctor immediately if you have unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
  • Call your doctor immediately if you have a fever, cough, or difficulty in breathing while taking TIGLUTIK.
  • If you miss or skip a dose of TIGLUTIK, do not take any extra dose to make up for those you missed, but take your prescribed dose at the next regularly scheduled time.
  • The most common side effects of TIGLUTIK that occurred during medical studies were numbness/tingling around the mouth, weakness, nausea, decreased lung function, high blood pressure, and abdominal pain. If any side effects become troublesome, contact your doctor.
  • Be sure to tell your doctor and pharmacist about all other health conditions you have and all medicines you are taking, including nonprescription products and vitamins. If you have questions, please talk to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-332-1088.

Please click here for the Full Prescribing Information.

Intended for U.S. Residents Only

ITF Pharma logo

©2021 ITF Pharma Inc. All rights reserved.  TIGLUTIK is a trademark of ITALFARMACO SA 

3 Paoli Plaza, Suite C
Paoli, PA 19301 United States
Medical/Product Inquiries: 844-763-1198
EDW Pharma US Headquarters: 610-937-6172